

## MATERIALS LICENSE

Amendment No. 01

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

302046

Licensee		In accordance with letter dated November 6, 1996	
1. Premier Pharmacy Services, P.C.		3. License Number 13-26472-01MD is amended in its entirety to read as follows:	
2. 1711 West 15th Street Indianapolis, IN 46202		4. Expiration Date May 31, 2004	
		5. Docket or Reference No. 030-33503	
6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License	
A. Molybdenum-99	A. Any Molybdenum-99/technetium-99m generator manufactured, labeled, packaged and distributed in accordance with a specific license issued pursuant to Section 32.73 of 10 CFR Part 32 or a specific license issued to the manufacturer by an Agreement State pursuant to equivalent State regulations	A. 35 curies	
B. Any byproduct material listed in paragraph 31.11(a) of 10 CFR Part 31	B. Prepackaged <u>in vitro</u> diagnostic test kits	B. 50 millicuries total possession limit	

190054

9612190273 961206  
PDR ADOCK 03033503  
C PDR

COPY

dl  
230  
SD

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number

13-26472-01MD

Docket or Reference Number

030-33503

Amendment No. 01

- |   |  |  |
|---|--|--|
| 6. Byproduct, source, and/or special nuclear material   | 7. Chemical and/or physical form   | 8. Maximum amount that licensee may possess at any one time under this license |
| C. Any byproduct material authorized under paragraph 35.14(d)(4) of 10 CFR Part 35 (superseded) or paragraph 35.57(a) of 10 CFR Part 35 (effective April 1, 1987) | C. Any sealed source listed in paragraph 35.14(d)(4) of 10 CFR Part 35 (superseded) or paragraph 35.57(a) of 10 CFR Part 35 (effective April 1, 1987) that has been manufactured, labeled, packaged and distributed in accordance with a specific license issued pursuant to Section 32.74 of 10 CFR Part 32 or a specific license issued to the manufacturer by an Agreement State pursuant to equivalent State regulations | C. 50 millicuries total for all sources authorized under Subitem 6.C.          |
| D. Xenon-133  | D. Unit dose containers of gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA  | D. 2.5 curie   |

COPY

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

13-26472-01MD

Docket or Reference Number

030-33503

Amendment No. 01

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

E. Iodine-131

E. Any form listed in Groups I through V of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Sections 35.100, 35.200, 35.300 of 10 CFR Part 35 (effective April 1, 1987)

E. 900 millicuries

F. Technetium-99m

F. Any form listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Sections 35.100, and 35.200 of 10 CFR Part 35 (effective April 1, 1987)

F. 35 curies

G. Any byproduct material, except iodine-131 and technetium-99m, listed in group I of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Section 35.100 of 10 CFR Part 35 (effective April 1, 1987)

G. Any form listed in Group I of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Section 35.100 of 10 CFR Part 35 (effective April 1, 1987)

G. 100 millicuries total possession limit

COPY

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number

13-26472-01MD

Docket or Reference Number

030-33503

Amendment No. 01

- |  |   |  |
|--|---|--|
| 6. Byproduct, source, and/or special nuclear material  | 7. Chemical and/or physical form  | 8. Maximum amount that licensee may possess at any one time under this license |
| H. Any byproduct material, except iodine-131 and technetium-99m, listed in Group II of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Section 35.200 of 10 CFR Part 35 (effective April 1, 1987) | H. Any form listed in Group II of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Section 35.200 of 10 CFR Part 35 (effective April 1, 1987)   | H. 400 millicuries total possession limit                                      |
| I. Any byproduct material, except iodine-131, listed in Group IV of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Section 35.300 of 10 CFR Part 35 (effective April 1, 1987)                    | I. Any form listed in Group IV of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Section 35.300 of 10 CFR Part 35 (effective April 1, 1987)   | I. 100 millicuries total possession limit                                      |
| J. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Sections 35.400 and 35.500 of 10 CFR Part 35 effective April 1, 1987                              | J. Any sealed source that has been manufactured, labeled, packaged and distributed in accordance with a specific license issued pursuant to Section 32.74 of 10 CFR Part 32 or a specific license issued to the manufacturer by an Agreement State pursuant to equivalent State regulations | J. 2.5 curies  |

COPY

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number

13-26472-01MD

Docket or Reference Number

030-33503

Amendment No. 01

- |   |                                     |  |
|---|-------------------------------------|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form    | 8. Maximum amount that licensee may possess at any one time under this license |
| K. Uranium (depleted in the isotope Uranium-235)      | K. Metal encased in stainless steel | K. 110 kilograms   |

## 9. Authorized Use:

- A. Production of technetium-99m pertechnetate. Redistribution of unused generators to authorized recipients in accordance with statements, representations and procedures contained in application dated January 24, 1993.
- B. Redistribution to general and specific licensees in accordance with statements, representations and procedures contained in application dated January 24, 1993.
- C. Instrument calibration. Redistribution of sources to specifically authorized recipients. Pursuant to Section 32.74 of 10 CFR Part 32, the licensee is authorized to redistribute sources to persons licensed pursuant to Sections 35.14 and 35.100 of 10 CFR Part 35 (superseded) or Section 35.57(a) of 10 CFR Part 35 (effective April 1, 1987) or under equivalent licenses of Agreement States.
- D. Distribution to authorized recipients.
- E. Dispensing and/or distribution of prepared radiopharmaceuticals to authorized recipients. Compounding of iodine-131 capsules and distribution of these capsules to authorized recipients in accordance with statements, representations and procedures contained in application dated January 24, 1993 and letters dated March 14, 1994 and May 10, 1994.
- F. Dispensing and/or distribution of prepared radiopharmaceuticals to authorized recipients. Use of technetium-99m pertechnetate for processing with reagent kits in preparing radiopharmaceuticals.
- G. through I. Dispensing and/or distribution of prepared radiopharmaceuticals to authorized recipients.
- J. Redistribution of sealed sources as received from the manufacturer in the manufacturer's original packaging and shielding and accompanied by the manufacturer's approved instructions to authorized recipients for use and storage.
- K. Shielding for Mo99/Tc99m generators.

COPY



MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number

13-26472-01MD

Docket or Reference Number

030-33503

Amendment No. 01

Pursuant to Sections 32.72, 32.73 and 32.74 of 10 CFR Part 32, the licensee is authorized to distributed the byproduct material described in Items 6 and 7 of this license to persons licensed pursuant to Sections 35.14 and 35.100 of 10 CFR Part 35 (superseded) or Sections 35.100, 35.200, 35.300, 35.400 and 35.500 of 10 CFR Part 35 (effective April 1, 1987), or under equivalent licenses of Agreement States, for the Groups or Sections indicated below:

- A. Unused molybdenum-99/technetium-99m generators may be redistributed to persons licensed pursuant to Group III or Section 10 CFR 35.200.
- D. Gas or gas in saline may be distributed to person licensed pursuant to 10 CFR 35.200 (effective April 1, 1987).
- E. through I. Any form listed in each group, Groups I, II, IV and V of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or authorized by Sections 35.100, 35.200, and 35.300 of 10 CFR Part 35 (effective April 1, 1987), may be distributed to persons licensed pursuant to that Group or Section.
- J. Sealed sources may be redistributed to persons licensed pursuant to Group VI or Sections 35.400 and 35.500 (effective April 1, 1987).

CONDITIONS

- 10. Licensed material shall be used only at the licensee's facilities located at 1711 West 15th Street, Indianapolis, Indiana.
- 11. A. Licensed material shall be used by, or under the supervision of:
  - (1) A pharmacist working or designated as an authorized nuclear pharmacist in accordance with 10 CFR 32.72(b)(2) and (4), or
  - (2) Authorized nuclear pharmacists: Jeffrey Dillon, C. Christopher Bultinck, Ron LaDuke or Stephen Piepenbrink.
- B. The Radiation Safety Officer for this license is Stephen Piepenbrink, R.Ph.
- 12. A. Sealed sources and detector cells shall be tested for leakage and/or contamination at intervals not to exceed 6 months or at such other intervals as specified by the certificate of registration referred to in 10 CFR 32.210.
- B. In the absence of a certificate from a transferor indicating that a leak test has been made within 6 months prior to the transfer, a sealed source or detector cell received from another person shall not be put into use until tested.

COPY

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number

13-26472-01MD

Docket or Reference Number

030-33503

Amendment No. 01

C. Sealed sources need not be leak tested if:

- (i) they contain only hydrogen-3; or
- (ii) they contain only a radioactive gas; or
- (iii) the half-life of the isotope is 30 days or less; or
- (iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or
- (v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

D. The leak test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(b)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region III, ATTN: Chief, Nuclear Materials Safety Branch, 801 Warrenville Road, Lisle, Illinois 60532-4351. The report shall specify the source involved, the test results, and corrective action taken.

E. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Commission or an Agreement State to Perform such services.

- 13. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
- 14. The licensee shall conduct a physical inventory every 6 months to account for all sources and/or devices received and possessed under the license.
- 15. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

COPY

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number  
13-26472-01MD

Docket or Reference Number  
030-33503

Amendment No. 01

16. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:
- A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.
  - B. Before disposal as ordinary trash, byproduct material shall be surveyed at the container surface with the appropriate survey meter set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.
  - C. A record of each disposal permitted under this License Condition shall be retained for three years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.
17. Radioactive waste may be picked up from the licensee's customers and disposed of in accordance with the procedures, statements, and representations in application dated January 24, 1993.
18. The licensee shall have quarterly audits of their radiation safety program, performed in accordance with statements contained in application dated January 24, 1993.
19. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated January 24, 1993; and
  - B. Letters dated March 14, 1994 (with enclosures); May 10, 1994 and November 6, 1996.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date December 6, 1996

By

Loren J. Hunter  
Nuclear Materials Licensing Branch, Region III

COPY



(FOR LFMS USE)  
INFORMATION FROM LTS

BETWEEN:

License Fee Management Branch, ARM  
and  
Regional Licensing Sections

Program Code: 02500  
Status Code: 0  
Fee Category: 3C 2B  
Exp. Date: 20040531  
Fee Comments:  
Decom Fin Assur Req'd N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: PREMIER PHARMACY SERVICES, P.C.  
Received Date: 961114  
Docket No: 3033503  
Control No.: 302046  
License No.: 13-26472-01MD  
Action Type: Amendment

2. FEE ATTACHED

Amount: 500  
Check No.: 2634

3. COMMENTS

Signed  
Date

A. Hershey  
11/14/96

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered / /)

1. Fee Category and Amount: (3C) 2B \$520

2. Correct Fee Paid. Application may be processed for:

Amendment ☒  
Renewal ☐  
License ☐

3. OTHER

Signed  
Date

SC  
12/5/96

DEC 09 1996

Log	Nov 9 III
Remitter	
Check No.	2634 / 2681
Amount	\$500+ / \$520
Fee Category	(3C) 2B
Type of Fee	Am.D
Date Check Rec'd	11/19/96
Date Completed	12/5/96
By:	SC

\$520

1996 NOV 19 AM 9:41

**PREMIER**  
PHARMACY SERVICES, P. C.

1711 West 15th Street  
Indianapolis, Indiana 46202  
317.464.9700  
800.464.6871

November 6, 1996

US Nuclear Regulatory Commission  
Region III  
801 Warrenville Road  
Lisle, IL 46532-4351  
Attn: Material Licensing Section


Dear Sir:

As required by 10 CFR Part 35.981, I am writing to request that Premier Pharmacy Services P.C. (License # 13-26472-01MD) be granted a license amendment to add an Authorized Nuclear Pharmacist. Please find the following attachments to this letter for adding Ron LaDuke as an Authorized Nuclear Pharmacist.

1. Chart of Training Received in Basic Radioisotope Handling Techniques
2. Chart Documenting Experience Handling Radioisotopes
3. Written Certification of Training by Preceptor ( 10CFR 35.980)
4. Check for \$500.00 license amendment fee

As we discussed on the telephone, I would greatly appreciate it if your could expedite this matter so that Ron may be added to our license as an authorized nuclear pharmacist as soon as possible. Should you have any questions concerning this matter, do not hesitate to contact me at (317) 464-9700.

Sincerely,



Stephen L. Piepenbrink, R.Ph. BCNP  
Radiation Safety Officer

**RECEIVED**

**NOV 14 1996**

**REGION III**

302046

**NOV 14 1996**

Pm: 11-12-96

## TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

Location of Training	Date(s) of Attendance	Course Title if Applicable	Total Clock Hours of Course	Breakdown of Course Content in Clock Hours								
				Radiation Physics & Instrumentation		Radiation Protection		Math Pertaining to Radioactivity		Radiation Biology		Radiopharmaceutical Chemistry
				A	B	A	B	A	B	A	B	A
Purdue University	August 1991 thru Dec. 1991	NUPH 412 & 413: Diagnostic Imaging I and II	32	15		6				7		4
Same as Above	January '93 thru May '93	NUPH 414: Nuclear Pharmacy Laboratory	60	35		6		6		3		10
Same as Above	August '93 thru Dec. 1993	NUPH 530: Applied Nuclear Pharmacy	77	23		12		10		10		22
Mallinckrodt Medical Ft. Lauderdale FL	5/16/94 thru 8/5/94	NUPH 416: Practicum in Nuclear Pharmacy	45		15		22		8			
Column "A" refers to a Lecture / Laboratory Course.			214	73	15	24	22	16	8	20	0	36
Column "B" refers to a Supervised Laboratory Experience.			TOTAL HOURS	88		46		24		20		36

(1996)

Figure A-2

DOCUMENTING EXPERIENCE HANDLING RADIOISOTOPES  
(Actual Use of Radioisotopes Under the Supervision of an Authorized User)

Name Ronald LaDuke

ISOTOPE	MAXIMUM AMOUNT USED AT ONE TIME	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE (actual clock hours)	TYPE OF USE (see key below)
Tc-99m	20 Ci	Mallinckrodt Medical Fort Lauderdale, FL	520 Hours	1 through 6
I-123	1 Ci			
Ga-67	1 Ci			
Tl-201	1 Ci			
Xe-133	2 Ci			
Se-75	250 mCi			
Co-57	10 mCi			
Cs-137	20 mCi			
Ba-133	277 uCi			
Co-60	1 mCi			
In-111	10 mCi			
I-131	1 Ci			
Cr-51	10 mCi			
I-125	5 mCi			
Fe-59	5 mCi			
P-32	35 mCi			

Key for Type of Use

The number or numbers entered under "Type of Use" correspond to experience in the following activities:

1. Ordering, receiving, and unpacking radioactive materials safely, including performing related radiation surveys.
2. Calibrating dose calibrators, scintillation detectors, and survey meters.
3. Calculating, preparing, and calibrating patient doses, including properly using radiation shields.
4. Following appropriate internal control procedures to prevent mislabeling errors.
5. Learning emergency procedures to handle and contain spilled materials safely, including related procedures for decontamination, surveys, and wipe tests.
6. Eluting technetium-99m generator systems, assaying the eluate for technetium-99m and for molybdenum-99, and processing the eluate with reagent kits to prepare technetium-99m-labeled radiopharmaceuticals.



RONALD PAUL LADUKE  
BIRTHDATE NOV. 08, 1970

WEST LAFAYETTE, IN 47907-1095

CLASS OF 1988  
COOPER CITY HIGH SCHOOL  
COOPER CITY FL

Course Number	Title	Comments	Cr. Hrs.	Grade	Pts.	Course Number	Title	Comments	Cr. Hrs.	Grade	Pts.
1988-1989	1ST SEMESTER	1 S 730	W LAFAYETTE			1990-1991	2ND SEMESTER	6 HLS 071	W LAFAYETTE		
AFT 110	AIR FORCE TODAY I		1.0 C	4.0		BCHM 207	BIOCHEMISTRY		3.0 A	18.0	
C S -180	PROGRAMMING I		4.0 F	9.0		BCHM 209	BIOCHEMISTRY LAB		1.0 B	5.0	
ENGL 103	ADVANCED FRESHMAN COMP		3.0 C	12.0		BIOL 295	MICRO TEACHING TECHS		3.0 A	18.0	
MA -161	PL ANLY GEO CALC I		5.0 F	10.0		MDCH-205	ORGANIC CHEM		4.0 D	12.0	
PSY -120	ELEMENTARY PSYCHOLOGY		3.0 D	9.0		SPV 374	SUPERVISORY MANAGEMENT		3.0 A	18.0	
	GRD 2.68 16.0 43.0	SEM 2.68	16.0	43.0		STAT 503	STAT METHODS BIOLOGY		3.0 C	12.0	
							GRD 5.09 74.0 377.0	SEM 4.88	17.0	83.0	
1988-1989	2ND SEMESTER	2 S 730	W LAFAYETTE			1991-1992	1ST SEMESTER	3 P 052	W LAFAYETTE		
A&D 113	BASIC DRAWING		3.0 B	15.0		BIOL 301	HUMAN DES ANTMY PHYSIO		3.0 B	15.0	
AFT 120	AIR FORCE TODAY II		1.0 B	5.0		CSR 342	PERSONAL FINANCE		3.0 B	15.0	
C S -180	PROGRAMMING I		4.0 D	12.0		ECON 210	PRIN OF ECONOMICS		3.0 B	15.0	
MA -161	PL ANLY GEO CALC I		5.0 C	20.0		<u>NUPH 412</u>	MED APPL OF RADIATION		1.0 A	6.0	
RUSS-101	1ST CRSE STD RUSSIAN		3.0 D	9.0		<u>NUPH-490</u>	RADIO PHARMACEUTICALS		1.0 A	6.0	
	GRD 3.73 23.0 86.0	SEM 3.81	16.0	61.0		PHPR 201	INTROD TO PHARMACY		1.0 P		
						PHPR 212	PRESCRIPTION SERVICES		2.0 A	12	
1989	SUMMER 06/08-08/02	3 S 790	W LAFAYETTE				GRD 5.12 87.0 446.0	SEM 5.30	13.0	69.0	
CHM 115	GENERAL CHEMISTRY		4.0 B	20.0		1991-1992	2ND SEMESTER	4 P 052	W LAFAYETTE		
COM 114	FUNDAMENT OF SPEECH		3.0 B	15.0		BIOL 302	HUMAN DES ANTMY PHYSIO		3.0 B	15.0	
	GRD 4.03 30.0 121.0	SEM 5.00	7.0	35.0		MDCH 205	ORGANIC CHEM		4.0 B	20.0	
1989-1990	1ST SEMESTER	3 HLS 071	W LAFAYETTE			PCTX 490	XENOBIOTIC METABOLISM		2.0 A	12.0	
BIOL 108	BIOLOGY OF PLANTS		3.0 B	15.0		PHAD 243	PHARMACY IN HC SYSTEM		3.0 B	15.0	
CHM 116	GENERAL CHEMISTRY		4.0 C	16.0			GRD 5.22 95.0 496.0	SEM 5.16	12.0	62.0	
MA 224	INTRO ANALYSIS II		3.0 B	15.0		1992	SUMMER 05/11-07/31	5 P 052	W LAFAYETTE		
PHPR 100	PHAR ORIENTATION I		1.0 P			MGMT 200	INTRO ACCOUNTING		3.0 B	15.0	
PHYS 225	PRINCIPLES PHYSICS I		3.0 C	12.0			GRD 5.21 98.0 511.0	SEM 5.00	3.0	15.0	
	GRD 4.28 39.0 167.0	SEM 4.46	13.0	58.0		1992-1993	1ST SEMESTER	5 P 052	W LAFAYETTE		
1989-1990	2ND SEMESTER	4 HLS 071	W LAFAYETTE			IPPH 362	BASIC PHARMACEUTIC I		3.0 B	15.0	
BIOL 109	BIOLOGY OF ANIMALS		3.0 A	18.0		ITAL 101	ITALIAN LEVEL I		3.0 B	15.0	
C S 110	INTRO TO COMPUTERS		3.0 A	18.0		MDCH 304	BIOLOGICAL CHEMISTRY		3.0 C	12.0	
PHPR 101	PHAR ORIENTATION II		1.0 P			MDCH 310	QUAN MEDIC CLNCL ANLYS		3.0 B	15.0	
PHYS 226	PRINCIPLES PHYSICS II		3.0 A	18.0		PCTX 490	XENOBIOTIC METABOLISM		2.0 W		
PSY 120	ELEMENTARY PSYCHOLOGY		3.0 A	18.0		PHAD 464	MGMT PROF PRACT		3.0 C	12.0	
RUSS 101	1ST CRSE STD RUSSIAN		3.0 A	18.0			GRD 5.13 113.0 580.0	SEM 4.60	15.0	69.0	
	GRD 4.97 48.0 239.0	SEM 6.00	15.0	90.0		1992-1993	2ND SEMESTER	6 P 052	W LAFAYETTE		
	DISTINGUISHED					IPPH 363	BASIC PHARMACEUTIC II		3.0 B	15.0	
1990-1991	1ST SEMESTER	5 HLS 071	W LAFAYETTE			MDCH-305	BIOLOGICAL CHEM II		3.0 D	9.0	
BIOL 221	INTRO TO MICROBIOLOGY		4.0 A	24.0		MDCH-422	IMMUNOLOGY & CHEMOTHPY		2.0 F	6.0	
MA 161	PL ANLY GEO CALC I		5.0 B	25.0		<u>NUPH 414</u>	NUCLEAR PHARMACY LAB		3.0 A	12.0	
MDCH 204	ORGANIC CHEM		4.0 B	20.0		PCTX 440	PATHOPHYSIOLOGY		3.0 C	12.0	
PES 115	TAI CHI CHUAN		1.0 A	6.0		PCTX 490	XENOBIOTIC METABILISM		3.0 A	18.0	
	GRD 5.15 57.0 294.0	SEM 5.35	14.0	75.0			GRD 5.01 130.0 652.0	SEM 4.23	17.0	72.0	
*****											

CONTINUED ON PAGE 2

RAISED SEAL NOT REQUIRED  
THIS OFFICIAL TRANSCRIPT DOES NOT  
REQUIRE A RAISED SEAL



"I CERTIFY THAT THIS IS A CORRECT  
TRANSCRIPT OF THE RECORD OF THE  
ABOVE STUDENT."

*Marlene A. Roney*  
REGISTRAR

FEDERAL LAW PROHIBITS THE RELEASE OF INFORMATION FROM THIS TRANSCRIPT  
WITHOUT THE WRITTEN CONSENT OF THE INDIVIDUAL WHOSE RECORD IT IS.

ALTERATION OR FORGERY OF THIS DOCUMENT IS A CRIMINAL OFFENSE.

EXPLANATION KEY AND AUTHENTICITY CONSERVATION INFORMATION ON REVERSE SIDE



Course Number	Title	Comments	Cr. Hrs.	Grade	Pts.	Course Number	Title	Comments	Cr. Hrs.	Grade	Pts.
*****						1994-1995	1ST SEMESTER	9 P 052	W LAFAYETTE		
*	PRIOR TO 1993 SUMMER SESSION,	*				CLPH-479	THERAP & PT CASE STUDY		4.0	F	0.0
*	INDEXES COMPUTED ON SCALE A=6.0, F=2.0.	*				FS 470	WINE APPRECIATION		3.0	B	9.0
*	BEGINNING 1993 SUMMER SESSION,	*				IPPH 471	PARENTERAL PRODUCTS		2.0	C	4.0
*	INDEXES COMPUTED ON SCALE A=4.0, F=0.0.	*				PHAD 472	JURISPRUDENCE		2.0	B	6.0
*****						PHPR 468	PATIENT SRVCS EXPERIEN		1.0	C	2.0
						GRD 2.88 163.0 470.0 SEM 1.75 12.0 21.0					
1993-1994	1ST SEMESTER	7 P 052	W LAFAYETTE			1994-1995	2ND SEMESTER	9 P 052	W LAFAYETTE		
IPPH 475	PHARMACOKINETICS I		3.0	B	9.0	PSY 310	SENSORY PERCEP PROC		3.0	N	
MDCH 407	MEDICINAL CHEM PCGY I		3.0	D	3.0	PSY 314	INTRO TO LEARNING		3.0	N	
MDCH 408	PHARMACOGNOSY LAB		1.0	C	2.0	SOC 100	INTRO SOCIOLOGY		3.0	N	
NUPH 530	APPLIED NUCLEAR PHARM		3.0	C	6.0	SOC 324	CRIMINOLOGY		3.0	N	
PCTX 441	INTRO PHARMACOLOGY I		3.0	C	6.0	GRD 2.88 163.0 470.0 SEM					
GRD 2.92 143.0 418.0 SEM 2.00 13.0 26.0						1995-1996	1ST SEMESTER	9 P 052	W LAFAYETTE		
1993-1994	2ND SEMESTER	8 P 052	W LAFAYETTE			CLPH 479	THERAP & PT CASE STUDY		4.0	C	8.0
MDCH 305	BIOLOGICAL CHEM II		3.0	B	9.0	GRD 2.93 163.0 478.0 SEM 2.00 4.0					
MDCH 408	MEDICINAL CHEM PCGY II		2.0	D	2.0	1995-1996	2ND SEMESTER	9 P 060	W LAFAYETTE		
MDCH 422	IMMUNOLOGY & CHEMOTHPY		3.0	C	6.0	CLPH 497	CLINICAL CLERKSHIP		3.0	P	
NUPH 490	ADV NUCLEAR PHARMACY		1.0	A	4.0	PHPR 499	EXTERNSHIP EXPERIENCE		12.0	P	
PCTX 442	INTRO PHARMACOLOGY II		3.0	C	6.0	GRD 2.93 163.0 478.0 SEM					
PCTX 443	PHARMACOL AND TOX LAB		1.0	B	3.0	BACHELOR OF SCIENCE IN PHARMACY					
PHPR 469	PRIN OF PHARM PRACT I		2.0	A	8.0	AWARDED AT WEST LAFAYETTE CAMPUS					
GRD 2.97 151.0 449.0 SEM 2.53 15.0 38.0						MAY 4, 1996					
1994 SUMMER 05/16-08/05	9 P 052	W LAFAYETTE				***** END OF RECORD *****					
NUPH 416	PRAC NUCLEAR PHARMACY		1.0	P							
GRD 2.97 151.0 449.0 SEM											
*****											

RAISED SEAL NOT REQUIRED  
THIS OFFICIAL TRANSCRIPT DOES NOT  
REQUIRE A RAISED SEAL



I CERTIFY THAT THIS IS A CORRECT  
TRANSCRIPT OF THE RECORD OF THE  
ABOVE STUDENT.

*Marlene A. Roney*  
REGISTRAR

FEDERAL LAW PROHIBITS THE RELEASE OF INFORMATION FROM THIS TRANSCRIPT  
WITHOUT THE WRITTEN CONSENT OF THE INDIVIDUAL WHOSE RECORD IT IS.

ALTERATION OR FORGERY OF THIS DOCUMENT IS A CRIMINAL OFFENSE.

EXPLANATION KEY AND AUTHENTICITY CONFIRMATION INFORMATION ON REVERSE SIDE.



Mallinckrodt Medical, Inc.  
Diagnostic Imaging Services  
5450 N.W. 33rd Ave., Suite 112  
Ft. Lauderdale, FL 33309  
Telephone (954) 735-8700  
Facsimile (954) 735-8704

November 6, 1996

US Nuclear Regulatory Commission  
Region III  
801 Warrenville Road  
Lisle, IL 46532-4351  
Attn: Material Licensing Section

Dear Sir:

This letter serves to notify you that Ronald Laduke has satisfactorily completed all aspects of the training outlined in 10CFR 35.980. Through that training, Ron has achieved a level of competency sufficient to independently operate a nuclear pharmacy.

Sincerely,

A handwritten signature in dark ink, appearing to read 'David Schmitt', written over a horizontal line.

David Schmitt, R Ph  
Authorized Nuclear Pharmacist Preceptor

## LICENSE FEE REQUIREMENTS

LICENSE FEE AND DEBT COLLECTION BRANCH  
DIVISION OF ACCOUNTING AND FINANCE  
OFFICE OF THE CONTROLLER  
U.S. NUCLEAR REGULATORY COMMISSION  
WASHINGTON, DC 20555-0001PREMIER PHARMACY SERVICES, P.C  
ATTN: STEPHEN L. PIPENBRINK, R.PH., BCNP  
RADIATION SAFETY OFFICER  
1711 WEST 15TH STREET  
INDIANAPOLIS, IN 46202

## TYPE OF ACTION

- ☐ NEW LICENSE
- ☐ RENEWAL OF LICENSE
- ☒ AMENDMENT TO LICENSE

## REQUESTED DATE

11-6-96

## LICENSE NUMBER

13-26472-01MD

## CONTROL NUMBER

302046

## I. APPLICATION FEE DUE

Your request for a licensing action is subject to the fee(s) in the category(ies) noted below in accordance with Section 170.31 of the enclosed Federal Register notice. Payment of the fee is required prior to the issuance of the license, renewal, or amendment.

FEE CATEGORY	APPLICATION	RENEWAL	AMENDMENT
3C	\$	\$	\$ 520.00
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$

FEE(s) DUE	\$	520.00
PAYMENT RECEIVED	\$	500.00
AMOUNT DUE	\$	20.00

☐ Your request was received without the prescribed application fee.

☒ We received your Check No. 2634 in the amount of \$ 500.00. Payment of the additional fee noted above is required.

☐ Your request will increase the scope of your license program. Therefore, your request is subject to the application fee(s) noted above. Refer to Section 170.31 and Footnote 1(d)(2).

☐ Your license expired prior to the receipt of your application for renewal. Therefore, your request is subject to the application fee(s) noted above. Refer to Section 170.31 and Footnote 1(a).

MAKE PAYMENT OF THE FEE(S) TO THE U.S. NUCLEAR REGULATORY COMMISSION AND MAIL THE PAYMENT TO THE ADDRESS LISTED AT THE TOP OF THIS FORM. IF WE DO NOT RECEIVE A REPLY FROM YOU WITHIN 30 CALENDAR DAYS FROM THE DATE LISTED BELOW, WE SHALL ASSUME THAT YOU DO NOT WISH TO PURSUE YOUR APPLICATION AND WILL VOID THIS ACTION.

SIGNATURE - LICENSE FEE ANALYST

LFDCB

LFDCB

SHIRLEY CRITCHFIELD

11/20/96

## II. FEE NOT REQUIRED

☐ Enclosed is Check No. \_\_\_\_\_ which accompanied your request. The fee is not required because:

☐ We received your Check No. \_\_\_\_\_ in payment of the fee.

☐ The Licensing staff has informed us that your request is to be considered as a continuation of your request dated \_\_\_\_\_, Control No. \_\_\_\_\_.

☐ Your request was combined, prior to review, with your \_\_\_\_\_ request, Control No. \_\_\_\_\_.

## III. CHECK RETURNED

☐ Enclosed is Check No. \_\_\_\_\_ which was returned to us by the bank for:

- ☐ INSUFFICIENT FUNDS
- ☐ ACCOUNT CLOSED
- ☐ OTHER

MAIL THE REPLACEMENT CHECK TO THE ADDRESS LISTED AT THE TOP OF THIS FORM AND REFERENCE THE ABOVE CONTROL NUMBER.

## IV. LICENSE ISSUED WITHOUT THE REQUIRED FEE

☐ License No. \_\_\_\_\_, Amendment No. \_\_\_\_\_, issued on \_\_\_\_\_ was issued without the required fee being collected. The fee required is noted in Section I of this form.

☐ The scope of your licensed program was increased. Therefore, your request is subject to the application fee(s) noted in Section I of this form. Refer to Section 170.31 and Footnote 1(d)(2).

☐ Because of the urgency of your request, the license was issued without remittance of the prescribed fee noted in Section I of this form.

Distribution:

Pending Fee File OC/DAF/SF(LF-3.2.7)

LFARB R/F (2)

Region 3

DATE

Nov. 20, 1996

DEC 09 1996

Stephen L. Piepenbrink, R.Ph. B.C.N.P.  
President  
Premier Pharmacy Services, P.C.  
1711 West 15th Street  
Indianapolis, IN 46202

Dear Mr. Piepenbrink:

Enclosed is Amendment No. 01 to your NRC Material License No. 13-26472-01MD in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

Please note that we have modified your license as discussed in our telecon on December 3, 1996, to confirm with regulatory changes that became effective in January 1995. This included deleting certain license conditions that are now covered by regulations or certain activities that are no longer regulated by the NRC.

This amendment also names "authorized nuclear pharmacist" to replace "authorized users", in accordance with current regulations. In order to expedite your amendment request, we limited the listing of authorized nuclear pharmacists to those authorized users listed in Condition No. 11. of your initial license, for whom you also provided a copy of their state pharmacy license or permit, verifying their status as a pharmacists.

If, at a later date, you wish to provide a copy of the state pharmacy license of other previous authorized users in Condition No. 11. of your initial license, you may provide that data as additional information to Control Number 302046 and we will amend your license without an additional fee, if the request does not include other changes subject to an amendment fee.

Also, please note we have added five years to the expiration date listed on your license. You will be receiving official notification from our headquarters office explaining the cause for the five-year extension in a few weeks. In the meantime, if you have any questions, please call me.

302046

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC, in writing, within 30 days:
  - a. When the Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or
  - b. When the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).
3. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license when you decide to terminate all activities involving materials authorized under the license.
4. Request and obtain a license amendment before you:
  - a. Change Radiation Safety Officers;
  - b. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;
  - c. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or
  - d. Change ownership of your organization.
5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.



S. Piepenbrink

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Policy and Procedures for NRC Enforcement Actions. Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Sincerely,

Original Signed By  
Loren J. Hueter  
Nuclear Materials Licensing Branch

License No. 13-26472-01MD  
Docket No. 030-33503

Enclosures:

1. Amendment No. 01
2. NRC Form 313

DOCUMENT NAME: M:\03033503.CL6

To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" =  
Copy with attachment/enclosure "N" = No copy

OFFICE	DNMS/RIII	<input checked="checked" type="checkbox"/>							
NAME	LJHueter:brt	<i>LJH</i>							
DATE	12/06/96								

OFFICIAL RECORD COPY

## CONVERSATION RECORD

TIME

DATE

12-3-96

☐ VISIT☐ CONFERENCE☒ TELEPHONE☐ INCOMING☒ OUTGOING

NAME OF PERSON(S) CONTACTED OR IN CONTACT

ORGANIZATION (OFFICE, DEPT. ETC.)

TELEPHONE NO.

Jeff Dillon

Premier Pharmacy

317-

464-9700

SUBJECT

CN 302046

SUMMARY

Mr Dillon said he would FAX ~~to~~ me a copy of ANP applicant, Ron LaDuke's state license as a pharmacist.

I also confirmed that Mr LaDuke's preceptor, David Schmidt, R.Ph. is an authorized nuclear pharmacist (ANP). (See Gallineworth Lic. No. 24-04206-11MD)

Also need copy of state license as a pharmacist for current individuals listed on license as authorized users before we can add to license as authorized nuclear pharmacist (ANP). In order to expedite amendment, we agreed he could provide copy of state pharmacy license of the authorized users currently working at Premier Pharmacy and later provide <sup>state</sup> pharmacy license of other previous authorized users as additional info to CN 302046.

ACTION REQUIRED

NAME OF PERSON DOCUMENTING CONVERSATION

SIGNATURE

DATE

Loren Hunter

12-3-96

ACTION TAKEN

SIGNATURE

TITLE

DATE

Fax Transmission Sheet

To: Lauren Hueter

Company: NRC

From: Steve Piepenbrink, R.Ph., BCNP  
Premier Pharmacy Services, P.C.  
Fax (317) 464-9702

Date \ Time 12/3/96 1000

RE: Ron LaDuke Permit

This is Page 1 of 2 Pages

Comments:

Please call if you have any questions.

*[Signature]* RPh

STATE OF INDIANA  
HEALTH PROFESSIONS BUREAU

RENEWAL NO. H913584  
LICENSE NO. 26018975

RONALD PAUL LA DUKE JR


IS DULY LICENSED AS PRESCRIBED BY INDIA LAWS AS A  
PHARMACIST

STATE BOARD OF PHARMACY

TO ENGAGE IN SUCH PURSUIT UNTIL 06/30/98

UNLESS SUSPENDED OR REVOKED

WRITTEN  
SIGNATURE



**PREMIER**  
PHARMACY SERVICES, P.C.

1711 White Hall Street  
Indianapolis, Indiana 46202  
317.464.9700  
800.464.6871

## Fax Transmission Sheet

To: Loren Hueter

Company: US NRC

From: Steve Piepenbrink, R.Ph., BCNP  
Premier Pharmacy Services, P.C.  
Fax (317) 464-9702

Date \ Time 12/3/96 1:30 pm

RE: License Amendment

This is Page 1 of \_\_\_\_\_ Pages

Comments::

Per your request



FORM APPROVED BY STATE BOARD OF ACCOUNTS 5/78

CUT ON DOTTED LINE FOR BILLFOLD

STATE OF INDIANA  
HEALTH PROFESSIONS BUREAU

RENEWAL NO. H730793

LICENSE NO. 26016569

STEPHEN L PIEPENBRINK

IS DULY LICENSED AS PRESCRIBER BY INDIANA LAW AS A  
PHARMACIST

STATE BOARD OF PHARMACY

TO ENGAGE IN SUCH PURSUIT UNTIL 06/30/96

UNLESS SUSPENDED OR REVOKED BY LAW

WRITTEN  
SIGNATURE

NOT VALID UNLESS SIGNED IN INK

Renewal No. H905914

## HEALTH PROFESSIONS BUREAU

402 West Washington Street  
Room 041  
Indianapolis, Indiana 46204

CONTROL NO. 963583 DEPOSIT DATE 06/17/96 FEE PAID 50.00

LIC # 26016569 EXP DATE 06/30/98 E

STEPHEN L PIEPENBRINK  
882 FRANKLIN TRACE  
ZIONSVILLE

IN 46077

STATE OF INDIANA  
HEALTH PROFESSIONS BUREAU

RENEWAL NO. H906526

LICENSE NO. 26018847

CHARLES C BULTINCK

IS DULY LICENSED AS PRESCRIBED BY INDIANA LAW AS A  
PHARMACIST

STATE BOARD OF PHARMACY

TO ENGAGE IN SUCH PRACTICE UNTIL 06/30/98

UNLESS SUSPENDED OR REVOKED BY LAW

WRITTEN  
SIGNATURE

NOT VALID ON THE BASIS OF THIS

# Indiana Board of Pharmacy

Be it known that this License is hereby granted to

**Jeffrey David Dillon**

who having complied with all the laws of the State of Indiana relating to the profession and having met all of the Requirements of the Board, is now a properly licensed

## Pharmacist

In testimony whereof, are hereby affixed our signatures and the seal of the Board this 17<sup>th</sup> Day of August, 1993.

**26018067**

License Number



President

Vice President

007302